Bill Hoon Chang, M.D., Ph.D.
- click here
- 503 346-0640 or 877 346-0640
Dr. Chang's research focuses on understanding the biochemical mechanism responsible for resistance in refractory and relapse leukemias. Identifying these mechanisms will aid in the development of new therapies for these resistant diseases. Using RNA interference technologies he has been able to identify new biochemical targets for therapy. Dr. Chang's research continues in collaboration with the Children's Oncology Group to develop these targets for new therapies to these cancers.
"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia,"
"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML,"
"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening,"
"Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia,"
"Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia,"